Challenges for biosimilars: focus on rheumatoid arthritis

References

• Carillo S, Mittermayr S, Farrell A, et al. Glycosylation analysis of therapeutic glycoproteins produced in CHO cells. Methods Mol Biol. 2017;1603:227–241.
   PubMedGoogle Scholar
• Research AM. World biosimilars/follow on biologics market – opportunities and forecasts. 2014.
   Google Scholar
• Levine HL, Cooney BR. The development of therapeutic monoclonal antibody products. Waltham (MA): BioProcess Technology Consultants, Inc; 2017.
   Google Scholar
• Emily Capra JS, Guang Y. Gene therapy coming of age: opportunities and challenges to getting ahead. Pharmaceuticals and Medical Products Practice. 2019.
   Google Scholar
• Hanna, C., Uccello, C. Prescription drug spending in the U.S. Healthcare System. Am Academy of Actuaries 2018. 1-12. Available from: www.actuary.org.
   Google Scholar
• Isaacs J, Gonçalves J, Strohal R, et al. The biosimilar approval process: how different is it? Considerations Med. 2017;1(1):3–6.
   Google Scholar
• Kogan LA. US biologics price competition and innovation Act of 2009 triggers public debates, regulatory/policy risks, and international trade concerns. Global Trade & Cust J. 2011;(6):513.
   Google Scholar
• Kirchhoff CF, Wang XM, Conlon HD, et al. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696–2705.
   PubMed Web of Science ®Google Scholar
• Reusch D, Haberger M, Falck D, et al. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: mass spectrometric methods. MAbs. 2015;7(4):732–742.
   PubMed Web of Science ®Google Scholar
• Christl L. FDA’s overview of the regulatory guidance for the development and approval of biosimilar products in the US. USA: US Food and Drug Administration. 2016.
   Google Scholar
• Olech E. Biosimilars: rationale and current regulatory landscape. Semin Arthritis Rheum. 45(5 Suppl):S1–S10.
   PubMed Web of Science ®Google Scholar
• Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis Rheum. 44(6 Suppl):S2–S8.
   PubMed Web of Science ®Google Scholar
• Laimer J, Hofer H, Fritz M, et al. MAESTRO-multi agent stability prediction upon point mutations. BMC Bioinformatics. 2015;16(1):116.
   PubMedGoogle Scholar
• Weise M, Bielsky M-C, De Smet K, et al. Biosimilars—why terminology matters. Nat Biotechnol. 2011;29(8):690–693.
   PubMed Web of Science ®Google Scholar
• Hamm M, Wang Y, Rustandi RR. Characterization of N-linked glycosylation in a monoclonal antibody produced in NS0 cells using capillary electrophoresis with laser-induced fluorescence detection. Pharmaceuticals. 2013;6(3):393–406.
   Google Scholar
• Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310–312.
   PubMed Web of Science ®Google Scholar
• Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol. 2003;21(3):255–261.
   PubMed Web of Science ®Google Scholar
• Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem. 2012;84(11):4637–4646.
   PubMed Web of Science ®Google Scholar
• Food U, Administration D. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Rockville (MD), US Food and Drug Administration; 2012.
   Google Scholar
• Sha S, Agarabi C, Brorson K, et al. N-Glycosylation design and control of therapeutic monoclonal antibodies. Trends Biotechnol. 2016;34(10):835–846.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466–3473.
   PubMed Web of Science ®Google Scholar
• St Amand MM, Tran K, Radhakrishnan D, et al. Controllability analysis of protein glycosylation in CHO cells. PLoS One. 2014;9(2):e87973.
   PubMed Web of Science ®Google Scholar
• Wooding KM, Peng W, Mechref Y. Characterization of pharmaceutical IgG and biosimilars using miniaturized platforms and LC-MS/MS. Curr Pharm Biotechnol. 2016;17(9):788–801.
   PubMed Web of Science ®Google Scholar
• Hong J, Lee Y, Lee C. et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade®(infliximab). MAbs. 2017;9(2):364–382.
   PubMed Web of Science ®Google Scholar
• Cho IH, Lee N, Song D. et al. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. MAbs. 2016;8(6):1136–1155.
   PubMed Web of Science ®Google Scholar
• Kozlowski S, Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv Drug Deliv Rev. 2006;58(5–6):707–722.
   PubMed Web of Science ®Google Scholar
• Dumont J, Euwart D, Mei B, et al. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol. 2016;36(6):1110–1122.
   PubMed Web of Science ®Google Scholar
• Lam SK, Ng TB. Lectins: production and practical applications. Appl Microbiol Biotechnol. 2011;89(1):45–55.
   PubMed Web of Science ®Google Scholar
• Dobson CL, Devine PW, Phillips JJ, et al. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep. 2016;6:38644.
   PubMed Web of Science ®Google Scholar
• Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323(9):844–853.
   PubMed Web of Science ®Google Scholar
• Farid SS, Baron M, Stamatis C, et al. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. Mabs. 2020;12(1):1754999.
   PubMed Web of Science ®Google Scholar
• Burchiel SW, Aspbury R, Munday J. The search for biosimilars and biobetters. Drug Discov Today. 2019;24(5):1087–1091.
   PubMed Web of Science ®Google Scholar
• Dan N, Setua S, Kashyap VK, et al. Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals. 2018;11(2):32.
   Web of Science ®Google Scholar
• European Medicines Agency. (2005). ICH Topic Q5E, comparability of Biotechnological/Biological products. Step 5, CPMP/ICH/5721/03, 1–13.
   Google Scholar
• Neubauer S, Cifaldi M, Mittendorf T, et al. Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Health Econ Rev. 2014;4(1):32.
   PubMedGoogle Scholar
• Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861–1874.
   PubMed Web of Science ®Google Scholar
• Malemud CJ, Blumenthal DE. Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives. World J Orthop. 2014;5(4):496–503.
   PubMedGoogle Scholar
• Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223:132–142.
   PubMed Web of Science ®Google Scholar
• Ozminkowski RJ, Burton WN, Goetzel RZ, et al. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med. 2006;48(2):135–148.
   PubMed Web of Science ®Google Scholar
• Albers JM, Kuper HH, van Riel PL, et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology. 1999;38(5):423–430.
   PubMed Web of Science ®Google Scholar
• Birnbaum H, Pike C, Kaufman R, et al. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010;26(1):77–90.
   PubMed Web of Science ®Google Scholar
• Zhang W, Anis AH. The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol. 2011;30(S1):25–32.
   Google Scholar
• Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. Clin Rheumatol. 2011;30(S1):3–8.
   Google Scholar
• Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology. 2000;39(1):28–33.
   PubMed Web of Science ®Google Scholar
• Yoon SJ, Bae SC, Lee SI, et al. Measuring the burden of disease in Korea. J Korean Med Sci. 2007;22(3):518–523.
   PubMed Web of Science ®Google Scholar
• Koenders MI, van den Berg WB. Novel therapeutic targets in rheumatoid arthritis. Trends Pharmacol Sci. 2015;36(4):189–195.
   PubMed Web of Science ®Google Scholar
• Foundation A. Arthritis By The Numbers Atlanta, USA. 2018; [cited 2019 Dec 22]. Available from: https://www.arthritis.org/Documents/Sections/About-Arthritis/arthritis-facts-stats-figures.pdf.
   Google Scholar
• Aj LB. The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. Joint Bone Spine. 2001;68(2):130–143.
   PubMed Web of Science ®Google Scholar
• Fauci A. Harrison’s principle of internal medicine. 18 ed. United States: McGraw Hill; 2011.
   Google Scholar
• Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. 2nd ed. New York: Oxford University Press; 2001.
   Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2(6):473–488.
   PubMed Web of Science ®Google Scholar
• Duke O, Panayi GS. The pathogenesis of rheumatoid arthritis. In Vivo. 1988;2(1):95–103.
   PubMedGoogle Scholar
• Jimenez-Boj E, Redlich K, Türk B, et al. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol. 2005;175(4):2579–2588.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–442.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med. 2000;51:207–229.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Liew FY. Cytokine networks–towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005;1(1):31–39.
   PubMedGoogle Scholar
• Gaujoux-Viala C, Nam J, Ramiro S, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2014;73(3):510–515.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977.
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375–382.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210–221.
   PubMed Web of Science ®Google Scholar
• Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2015;74(6):979–984.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Morel J, Perrodeau E, et al. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ. 2019;364:l67.
   PubMedGoogle Scholar
• Gottenberg JE, Brocq O, Perdriger A, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172–1180.
   PubMed Web of Science ®Google Scholar
• Teitsma XM, Marijnissen AK, Bijlsma JW, et al. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. Arthritis Res Ther. 2016;18(1):211.
   PubMedGoogle Scholar
• Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19–26.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675–681.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Buckley F, Dejonckheere F, et al. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs–a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12(1):102.
   PubMedGoogle Scholar
• Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Invest Drugs. 2008;17(3):349–359.
   PubMed Web of Science ®Google Scholar
• Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096–1103.
   PubMed Web of Science ®Google Scholar
• Cabral VP, Andrade CA, Passos SR, et al. Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies. Rev Bras Reumatol Engl Ed. 2016;56(6):543–550.
   PubMedGoogle Scholar
• Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68(1):25–32.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454–1462.
   PubMed Web of Science ®Google Scholar
• Vinson D, Molet-Benhamou L, Degboe Y, et al. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. Arthritis Res Ther. 2020;22(1):97.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101–1136.
   PubMed Web of Science ®Google Scholar
• Dreyer L, Cordtz RL, Hansen IMJ, et al. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. Ann Rheum Dis. 2018;77(4):510–514.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338–2348.
   PubMed Web of Science ®Google Scholar
• Verden A, Dimbil M, Kyle R, et al. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41(4):357–361.
   PubMed Web of Science ®Google Scholar
• Kaufman MB. Pharmaceutical approval update. P T. 2018;43(9):528–530.
   PubMedGoogle Scholar
• EMA. Xeljanz 2019. [updated 5-7-2019; cited 2020 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz.
   Google Scholar
• FDA. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). 2019; [updated 28-8-2019; cited 2019 Oct 15]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and
   Google Scholar
• Becede M, Alasti F, Gessl I, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum. 2019;49(2):211–217.
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–279.
   PubMed Web of Science ®Google Scholar
• Azevedo VF, Galli N, Kleinfelder A, et al. Etanercept biosimilars. Rheumatol Int. 2015;35(2):197–209.
   PubMed Web of Science ®Google Scholar
• Hess A, Axmann R, Rech J, et al. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci USA. 2011;108(9):3731–3736.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85(3):307–310.
   PubMed Web of Science ®Google Scholar
• Vervoordeldonk MJ, Tak PP. Cytokines in rheumatoid arthritis. Curr Rheumatol Rep. 2002;4(3):208–217.
   PubMedGoogle Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
   PubMed Web of Science ®Google Scholar
• Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27–37.
   PubMedGoogle Scholar
• Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005;7(4):R784–R795.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan F, Bondeson J, et al. Analysis of cytokine expression in rheumatoid synovium has provided new insights into the pathogenesis of rheumatoid arthritis and new therapeutic opportunities. Transplant Proc. 2001;33(3):2085–2086.
   PubMed Web of Science ®Google Scholar
• Rossi JF, Lu ZY, Jourdan M, et al. Interleukin-6 as a therapeutic target. Clin Cancer Res. 2015;21(6):1248–1257.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN, Bondeson J, et al. Cytokine blockade in rheumatoid arthritis. Adv Exp Med Biol. 2001;490:119–127.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19(1):163–196.
   PubMedGoogle Scholar
• Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43(1):38–47.
   PubMed Web of Science ®Google Scholar
• Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother. 2004;5(3):581–594.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Nguyen CT, Raychaudhuri SK, et al. Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun Rev. 2009;9(2):67–81.
   PubMed Web of Science ®Google Scholar
• Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986;322(6079):547–549.
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–1593.
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932–1939.
   PubMed Web of Science ®Google Scholar
• Maini RN, Elliott M, Brennan FM, et al. TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. APMIS. 1997;105(4):257–263.
   PubMed Web of Science ®Google Scholar
• Bhatnagar R, Penfornis H, Mauviel A, et al. Interleukin-1 inhibits the synthesis of collagen by fibroblasts. Biochem Int. 1986;13(4):709–720.
   PubMedGoogle Scholar
• Smolen JS, Weinblatt ME. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? Ann Rheum Dis. 2008;67(11):1497–1498.
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381–3390.
   PubMed Web of Science ®Google Scholar
• Gerlag DM, Tak PP. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol. 2008;22(2):311–323.
   PubMed Web of Science ®Google Scholar
• Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;334(8657):244–247.
   Google Scholar
• Bystrom J, Clanchy FI, Taher TE, et al. Response to treatment with TNFalpha inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF(+) T lymphocytes. Clin Rev Allergy Immunol. 2017;53(2):265–276.
   PubMed Web of Science ®Google Scholar
• Polzer K, Baeten D, Soleiman A, et al. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints. Ann Rheum Dis. 2008;67(11):1610–1616.
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Pakozdi A, Szentpetery A, et al. Chemokines and angiogenesis in rheumatoid arthritis. Front Biosci. 2009;1:44–51.
   Google Scholar
• Bradfield PF, Amft N, Vernon-Wilson E, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum. 2003;48(9):2472–2482.
   PubMedGoogle Scholar
• Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4 (Suppl 2):S22–S28.
   PubMedGoogle Scholar
• Lim H, Lee SH, Lee HT, et al. Structural biology of the TNFalpha antagonists used in the treatment of rheumatoid arthritis. Int J Mol Sci. 2018;19(3):768.
   Web of Science ®Google Scholar
• Chen X, DuBois DC, Almon RR, et al. Interrelationships between Infliximab and recombinant tumor necrosis factor-alpha in plasma using minimal physiologically based pharmacokinetic models. Drug Metab Dispos. 2017;45(7):790–797.
   PubMed Web of Science ®Google Scholar
• Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. MAbs. 2016;8(7):1177–1194.
   PubMed Web of Science ®Google Scholar
• Jespers LS, Roberts A, Mahler SM, et al. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Nat Biotechnol. 1994;12(9):899–903.
   Google Scholar
• Grazio S. [Adalimumab (Humira)-efficacy in rheumatoid arthritis treatment with particular reference to working ability]. Reumatizam. 2008;55(2):62–67.
   PubMedGoogle Scholar
• Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15.
   PubMed Web of Science ®Google Scholar
• Keystone E, Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am. 2004;30(2):349–364.
   PubMed Web of Science ®Google Scholar
• Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137–147.
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451–1458.
   PubMed Web of Science ®Google Scholar
• Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002;54(4):531–545.
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol. 1999;17(8):780–783.
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323–1332.
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason D, Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319–3329.
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797–804.
   PubMed Web of Science ®Google Scholar
• Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348(1–2):36–41.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423–441.
   PubMed Web of Science ®Google Scholar
• Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015;74(1):96–103.
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC, Jr., Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402–3412.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976–986.
   PubMed Web of Science ®Google Scholar
• Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther. 2008;10(4):393–406.
   PubMedGoogle Scholar
• Emery P, Fleischmann RM, Strusberg I, et al. Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial. Arthritis Care Res. 2016;68(6):744–752.
   PubMed Web of Science ®Google Scholar
• Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49(9):1056–1070.
   PubMed Web of Science ®Google Scholar
• Caporali R, Caprioli M, Bobbio-Pallavicini F, et al. DMARDS and infections in rheumatoid arthritis. Autoimmun Rev. 2008;8(2):139–143.
   PubMed Web of Science ®Google Scholar
• Zidi I, Mestiri S, Bartegi A, et al. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27(2):185–198.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68(6):789–796.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272–2283.
   PubMed Web of Science ®Google Scholar
• Acevedo-Vasquez E, Ponce de Leon D, Gamboa-Cardenas R. Latent infection and tuberculosis disease in rheumatoid arthritis patients. Rheum Dis Clin North Am. 2009;35(1):163–181.
   PubMed Web of Science ®Google Scholar
• Dumitru RB, Horton S, Hodgson R, et al. A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). BMC Musculoskelet Disord. 2016;17:61.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130(6):478–486.
   PubMed Web of Science ®Google Scholar
• Madhusudan S, Muthuramalingam SR, Braybrooke JP, et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol. 2005;23(25):5950–5959.
   PubMed Web of Science ®Google Scholar
• Mears JB, Huynh-Duc L, Fiechtner JJ. A patient with rheumatoid arthritis on methotrexate and etanercept who developed Pasteurella multocida Bacteremia. J Clin Rheumatol. 2015;21(8):457. Dec
   PubMed Web of Science ®Google Scholar
• Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74(2):354–360.
   PubMed Web of Science ®Google Scholar
• McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405–417.
   PubMed Web of Science ®Google Scholar
• Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis. 2013;72(10):1589–1593.
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs. 2013;5(5):621–623.
   PubMed Web of Science ®Google Scholar
• Rinaudo-Gaujous M, Paul S, Tedesco ED, et al. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther. 2013;38(8):914–924.
   PubMed Web of Science ®Google Scholar
• Hlavaty T, Letkovsky J. Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2014;26(6):581–587.
   PubMed Web of Science ®Google Scholar
• Genazzani A, Altomare G, Balato N, et al. Biosimilar infliximab: an expert view. G Ital Dermatol Venereol. 2015;150(4):449–459.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves first biosimilar product Zarxio: FDA; 2015; [cited 2016 Feb 16]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm.
   Google Scholar
• Ledford H. Biosimilar’ drugs poised to penetrate market. Nature. 2010;468(7320):18–19.
   PubMed Web of Science ®Google Scholar
• Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. MAbs. 2014;6(5):1163–1177.
   PubMed Web of Science ®Google Scholar
• Tang H, Hsueh P, Kletter D, et al. The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities. Adv Cancer Res. 2015;126:167–202.
   PubMed Web of Science ®Google Scholar
• Zhang P, Woen S, Wang T, et al. Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs. Drug Discov Today. 2016;21(5):740–765.
   PubMed Web of Science ®Google Scholar
• Ahmadi S, Davami F, Davoudi N, et al. Monoclonal antibodies expression improvement in CHO cells by PiggyBac transposition regarding vectors ratios and design. PLoS One. 2017;12(6):e0179902.
   PubMed Web of Science ®Google Scholar
• Krambeck FJ, Bennun SV, Andersen MR, et al. Model-based analysis of N-glycosylation in Chinese hamster ovary cells. PLoS One. 2017;12(5):e0175376.
   PubMed Web of Science ®Google Scholar
• Magnelli PE, Bielik AM, Guthrie EP. Identification and characterization of protein glycosylation using specific endo- and exoglycosidases. J Vis Exp. 2011;26(58):e3749.
   Google Scholar
• Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci. 2009;30(7):356–362.
   PubMed Web of Science ®Google Scholar
• Cao M, De Mel N, Shannon A, et al. Charge variants characterization and release assay development for co-formulated antibodies as a combination therapy. MAbs. 2019;11(3):489–499.
   PubMed Web of Science ®Google Scholar
• Duivelshof BL, Fekete S, Guillarme D, et al. A generic workflow for the characterization of therapeutic monoclonal antibodies-application to daratumumab. Anal Bioanal Chem. 2019;411(19):4615–4627.
   PubMed Web of Science ®Google Scholar
• Gomes RA, Almeida C, Correia C, et al. Exploring the analytical power of the QTOF MS platform to assess monoclonal antibodies quality attributes. PLoS One. 2019;14(7):e0219156.
   PubMed Web of Science ®Google Scholar
• Lee JH, Paek K, Moon JH, et al. Biological characterization of SB3, a trastuzumab biosimilar, and the influence of changes in reference product characteristics on the similarity assessment. BioDrugs. 2019;33(4):411–422.
   PubMed Web of Science ®Google Scholar
• Lippold S, Nicolardi S, Dominguez-Vega E, et al. Glycoform-resolved FcRIIIa affinity chromatography-mass spectrometry. MAbs. 2019;11(7):1191–1196.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves Inflectra, a biosimilar to Remicade: FDA; 2016; [cited 2016 Jun 28]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm.
   Google Scholar
• Blair HA, Deeks ED. Infliximab biosimilar (CT-P13; Infliximab-dyyb): a review in autoimmune inflammatory diseases. BioDrugs. 2016;30(5):469–480.
   PubMed Web of Science ®Google Scholar
• Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705–1712.
   PubMed Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612.
   PubMed Web of Science ®Google Scholar
• Ahrweiler S. ACR Response Criteria: PhuseWiki; 2012; [cited 2020 Oct 03]. Available from: https://www.phusewiki.org/wiki/index.php?title=ACR_Response_Criteria.
   Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):51–57.
   PubMed Web of Science ®Google Scholar
• Bae SC, Kim J, Choe JY, et al. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Ann Rheum Dis. 2017;76(1):65–71.
   PubMed Web of Science ®Google Scholar
• Castaneda-Hernandez G, Szekanecz Z, Mysler E, et al. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine. 2014;81(6):471–477.
   PubMed Web of Science ®Google Scholar
• EMA. FLIXABI: EUROPEAN MEDICINE AGENCY; 2016; [cited 2016 Jun 26]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004020/human_med_001980.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Takeuchi T, Yamanaka H, Tanaka Y, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25(6):817–824.
   PubMed Web of Science ®Google Scholar
• EMA. Benepali: EUROPEAN MEDICINES AGENCY; 2016; [cited 2016 June 18]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004007/human_med_001944.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Chadwick L, Zhao S, Mysler E, et al. Review of biosimilar trials and data on etanercept in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(12):84.
   PubMed Web of Science ®Google Scholar
• Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72(3):315–318.
   PubMed Web of Science ®Google Scholar
• Castaneda-Hernandez G, Gonzalez-Ramirez R, Kay J, et al. Biosimilars in rheumatology: what the clinician should know. RMD Open. 2015;1(1):e000010–e000010.
   PubMed Web of Science ®Google Scholar
• Zhao S, Chadwick L, Mysler E, et al. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(10):57.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis. Br J Dermatol. 2017;177(6):1562–1574.
   PubMed Web of Science ®Google Scholar
• Markus R, McBride HJ, Ramchandani M, et al. A review of the totality of evidence supporting the development of the first adalimumab biosimilar ABP 501. Adv Ther. 2019;36(8):1818–1833.
   Web of Science ®Google Scholar
• Dorner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11(12):713–724.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Van Stappen T, Jairath V, et al. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42(10):1158–1169.
   PubMed Web of Science ®Google Scholar
• Geiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des. 2011;17(29):3141–3154.
   PubMed Web of Science ®Google Scholar
• Lai Z, La Noce A. Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. RMD Open. 2016;2(1):e000154.
   PubMed Web of Science ®Google Scholar
• Jayaraman K. India’s Cipla sets sights on avastin, herceptin and enbrel. Nat Biotechnol. 2010;28(9):883–884.
   PubMed Web of Science ®Google Scholar
• Roy PS, John S, Karankal S, et al. Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol. 2013;34(4):292.
   PubMedGoogle Scholar
• Midha V, Mahajan R, Mehta V, et al. Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis. Intest Res. 2018;16(1):83–89.
   PubMed Web of Science ®Google Scholar
• Statista. Top 10 pharmaceutical products by sales worldwide in 2015 (in billion U.S. dollars): The Statistics Portal; 2016. [cited 2016 Jun 26]. Available from: http://www.statista.com/statistics/258022/top-10-pharmaceutical-products-by-global-sales-2011/.
   Google Scholar
• Meier FM, McInnes IB. Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Res Clin Rheumatol. 2014;28(4):605–624.
   PubMed Web of Science ®Google Scholar
• Simmons DL. Targeting kinases: a new approach to treating inflammatory rheumatic diseases. Curr Opin Pharmacol. 2013;13(3):426–434.
   PubMed Web of Science ®Google Scholar
• Cohen MD, Keystone EC. JAK inhibitors for rheumatoid arthritis. Curr Treat Options in Rheum. 2015;1(4):305–319.
   Google Scholar
• Kavanaugh A, Smolen JS, Emery P, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum. 2009;61(11):1592–1600.
   PubMedGoogle Scholar
• Scheinberg MA, Azevedo VF. Biosimilars in rheumatology: perspective and concerns. Rheumatology. 2014;53(3):389–390.
   PubMed Web of Science ®Google Scholar
• Expensive treatments for genetic disorders are arriving. But who should foot the bill? Nature Editorial. 2019:576:7–8.
   Google Scholar